
## Sha Zhao

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4453680/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer. Lung Cancer, 2019, 130, 10-17.	0.9	119
2	EGFRâ€ŧargeted therapy alters the tumor microenvironment in EGFRâ€driven lung tumors: Implications for combination therapies. International Journal of Cancer, 2019, 145, 1432-1444.	2.3	112
3	Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M. Lung Cancer, 2019, 128, 33-39.	0.9	34
4	<p>Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer</p> . OncoTargets and Therapy, 2020, Volume 13, 6475-6483.	1.0	33
5	Galectin-9 in non-small cell lung cancer. Lung Cancer, 2019, 136, 80-85.	0.9	32
6	T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, 895-906.	1.3	29
7	Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice. Lung Cancer, 2019, 137, 85-93.	0.9	24
8	Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer. Lung Cancer, 2018, 125, 22-28.	0.9	16
9	The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review. Translational Lung Cancer Research, 2021, 10, 1029-1038.	1.3	12
10	Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage l–III small cell lung cancer. , 2021, 9, e002554.		11
11	Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment. Frontiers in Oncology, 2021, 11, 713853.	1.3	8
12	Comparison between the first-line and second-line immunotherapy drugs in the progression-free survival and overall survival in advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. Annals of Palliative Medicine, 2021, 10, 1717-1726.	0.5	6
13	Analysis of prognostic and therapeutic values of drug resistance-related genes in the lung cancer microenvironment. Translational Cancer Research, 2022, 11, 339-357.	0.4	4